Recently, our firm won the first instance of an administrative litigation case for invalidation of an invention patent, in which it is ruled that the invention patent should be comp...
Introduction In the chemical field, it is difficult to seek invalidation of a patent claiming to have achieved unexpected technical effect. This case provides a strategy for success...
Linda Liu IP reunited with the IP Forefront Pharma Forum in beautiful Suzhou
Linda Liu & Partners sponsored and participated in the 9th Intellectual Frontier Pharmaceutical Forum (2024 IFPF) from October 16-18. Mr. Wang Junshun, the partner from Beijing headquarters, and Dr. Hao ZHANG, the manager of the Suzhou office, led the team to participate.
During the conference, Linda Liu team engaged in discussions on critical topics, including mRNA drugs, gene and cell therapy, ADC drugs, Chinese medicine, the new policy on PTE, and the mechanism for early resolution of pharmaceutical patent disputes, and reconnected with numerous old and new friends from home as well as abroad. There was also a discussion among speakers and participants from 15 countries and regions worldwide regarding the most recent advancements and forthcoming challenges in pharmaceutical intellectual property rights.
